Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two clinically and phenotypically different subgroups of individuals with recent onset Stage 3 type 1 diabetes

Guido Sebastiani, Giuseppina Emanuela Grieco, Marco Bruttini, Stefano Auddino, Alessia Mori, Mattia Toniolli, Daniela Fignani, Giada Licata, Laura Nigi, Caterina Formichi, Alberto Pugliese, Carmella Evans-Molina, Lut Overbergh, Timothy Tree, Mark Peakman, Chantal Mathieu, Francesco Dotta INNODIA investigators
doi: https://doi.org/10.1101/2023.10.08.23296650
Guido Sebastiani
1Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
2Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppina Emanuela Grieco
1Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
2Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Bruttini
1Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
2Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
3Tuscany Centre for Precision Medicine (CReMeP), Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Auddino
1Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
2Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessia Mori
1Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
2Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
3Tuscany Centre for Precision Medicine (CReMeP), Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mattia Toniolli
1Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
2Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Fignani
1Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
2Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giada Licata
1Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
2Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Nigi
1Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
2Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caterina Formichi
1Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
2Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto Pugliese
4Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, FL, USA
5Department of Diabetes Immunology, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmella Evans-Molina
6Center for Diabetes and Metabolic Diseases and the Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lut Overbergh
7Katholieke Universiteit Leuven/Universitaire Ziekenhuizen, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Tree
8Department of Immunobiology, King’s College London, School of Immunology and Microbial Sciences, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Peakman
9Immunology & Inflammation Research Therapeutic Area, Sanofi, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantal Mathieu
7Katholieke Universiteit Leuven/Universitaire Ziekenhuizen, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Dotta
1Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
2Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy
3Tuscany Centre for Precision Medicine (CReMeP), Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: francesco.dotta{at}unisi.it
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

SUMMARY

Previous research has indicated that circulating microRNAs are linked to the onset and progression of type 1 diabetes mellitus (T1DM), making them potential biomarkers for the disease. In this study, we employed a multiplatform sequencing approach to analyze circulating microRNAs in an extended cohort of individuals recently diagnosed with T1DM from the European INNODIA consortium. Our findings revealed that a specific set of microRNAs located within the T1DM susceptibility chromosomal locus 14q32 distinguishes two distinct subgroups of T1DM individuals. To validate our results, we conducted additional analyses on a second cohort of T1DM individuals, independently confirming the identification of these two subgroups, which we have named Cluster A and Cluster B. Remarkably, Cluster B T1DM individuals, who exhibited increased expression of 14q32 miRNAs, displayed a different peripheral blood immunomics profile, possessed a lower T1DM risk HLA genotype, and showed better glycaemic control during follow-up visits compared to Cluster A individuals. Taken together, our findings suggest that this specific set of circulating microRNAs located in the 14q32 locus can effectively identify T1DM subgroups with distinct characteristics and different clinical outcomes during follow-up.

Figure
  • Download figure
  • Open in new tab

HIGHLIGHTS

  • Circulating miRNA profiles in individuals with newly diagnosed Type 1 Diabetes Mellitus (T1DM) can distinguish two subgroups: Cluster A and Cluster B.

  • miR-409-3p, miR-127-3p, and miR-382-5p are increased in the plasma of individuals in Cluster B.

  • Individuals in Cluster B showed lower IAA titers, a reduced prevalence of HLA risk genotype, and an improved glycaemic profile during the follow-up period.

  • Immunomic profiling revealed a reduced frequency of pro-inflammatory immune cells and a higher frequency of exhausted T lymphocytes among individuals in Cluster B.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The work is supported by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement No.115797-INNODIA and No.945268 INNODIA HARVEST. This joint undertaking receives support from the EU Horizon 2020 research and innovation programme and EFPIA, JDRF and The Leona M. and Harry B. Helmsley Charitable Trust. GS is supported by University of Siena within F-CUR funding program Grant No. 2268-2022-SG-PSR2021-FCUR_001. FD was supported by the Italian Ministry of University and Research (2017KAM2R5_003). This work is also supported by EU within Italian Ministry of University and Research (MUR) PNRR National Center for Gene Therapy and Drugs based on RNA Technology (Project No. CN00000041 CN3 Spoke 5 Inflammatory and Infectious Diseases. This work is also supported by JDRF and The Leona M. and Harry B. Helmsley Charitable Trust for the project: Collaborative Effort to Identify and Validate miRNA as Biomarkers of T1D.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study followed the guidelines of the Declaration of Helsinki for research on human individuals, and the study was approved by the local ethical committees of the participating clinical sites: CHL - Centre Hospitalier de Luxembourg, Luxembourg HH-RH - Herlev University Hospital, Copenhagen-Denmark HKA - Hannoversche Kinderheilanstalt, Hannover-Germany IT- Ospedale Pediatrico Bambino Gesu, Roma- Italy KU Leuven, Leuven- Belgium MUG - Medical University of Graz, Graz- Austria SUM - Slaski Uniwersytet Medyczny w Katowicach, Katovice, Poland UCAM - University of Cambridge, Cambridge- UK UH - University of Helsinki, Helsinki- Finland UK- Barts Health NHS Trust, London- UK UK - Leicester Royal Infirmary, Leicester- UK ULB - Universite Libre de Bruxelles, Bruxelles- Belgium ULI - University of Ljubljana, Ljiubljana- Slovenia UNISI - Universita degli Studi di Siena, Siena-Italy UOUL - Oulun Yliopisto, Oulu, Finland Participants gave written informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • ↵10 Lead Contact

  • ↵* Shared First co-authorship

  • ↵§ INNODIA: “Innovative approaches to understanding and arresting type 1 diabetes”- List of contributors included with submission.

Data Availability and Code availability

The generated data is person-sensitive and access can be provided by application to the INNODIA Data Access Committee. Any additional information regarding the data reported in this paper is available from the lead contact upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 09, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two clinically and phenotypically different subgroups of individuals with recent onset Stage 3 type 1 diabetes
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two clinically and phenotypically different subgroups of individuals with recent onset Stage 3 type 1 diabetes
Guido Sebastiani, Giuseppina Emanuela Grieco, Marco Bruttini, Stefano Auddino, Alessia Mori, Mattia Toniolli, Daniela Fignani, Giada Licata, Laura Nigi, Caterina Formichi, Alberto Pugliese, Carmella Evans-Molina, Lut Overbergh, Timothy Tree, Mark Peakman, Chantal Mathieu, Francesco Dotta
medRxiv 2023.10.08.23296650; doi: https://doi.org/10.1101/2023.10.08.23296650
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two clinically and phenotypically different subgroups of individuals with recent onset Stage 3 type 1 diabetes
Guido Sebastiani, Giuseppina Emanuela Grieco, Marco Bruttini, Stefano Auddino, Alessia Mori, Mattia Toniolli, Daniela Fignani, Giada Licata, Laura Nigi, Caterina Formichi, Alberto Pugliese, Carmella Evans-Molina, Lut Overbergh, Timothy Tree, Mark Peakman, Chantal Mathieu, Francesco Dotta
medRxiv 2023.10.08.23296650; doi: https://doi.org/10.1101/2023.10.08.23296650

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Endocrinology (including Diabetes Mellitus and Metabolic Disease)
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)